Prime Medicine (PRME) and Its Peers Critical Contrast

Prime Medicine (NYSE:PRME) is one of 273 public companies in the “Biological products, except diagnostic” industry, but how does it compare to its peers? We will compare Prime Medicine to related businesses based on the strength of its risk, dividends, institutional ownership, valuation, profitability, analyst recommendations and earnings.

Profitability

This table compares Prime Medicine and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Prime Medicine	N/A	-67.28%	-57.83%
Prime Medicine Competitors	-4,741.91%	-286.58%	-48.98%

Institutional & Insider Ownership

47.4% of Prime Medicine shares are held by institutional investors. Comparatively, 44.4% of shares of all “Biological products, except diagnostic” companies are held by institutional investors. 24.3% of Prime Medicine shares are held by insiders. Comparatively, 16.7% of shares of all “Biological products, except diagnostic” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Prime Medicine and its peers gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Prime Medicine	$5.21 million	-$121.82 million	-3.27
Prime Medicine Competitors	$527.62 million	$82.23 million	-2.46

Prime Medicine’s peers have higher revenue and earnings than Prime Medicine. Prime Medicine is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Prime Medicine and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prime Medicine	0	1	4	0	2.80
Prime Medicine Competitors	1233	4135	10672	151	2.60

Prime Medicine presently has a consensus target price of $21.60, indicating a potential upside of 227.27%. As a group, “Biological products, except diagnostic” companies have a potential upside of 82.45%. Given Prime Medicine’s stronger consensus rating and higher possible upside, analysts plainly believe Prime Medicine is more favorable than its peers.

Summary

Prime Medicine beats its peers on 7 of the 12 factors compared.

Prime Medicine Company Profile

Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. Prime Medicine, Inc. was incorporated in 2019 and is based in Cambridge, Massachusetts.